

Ref: 111/SE/LC/2024-25

Date: 21/03/2025

To,

**Head, Listing Compliance Department  
BSE Limited**

Phiroze Jeejeebhoy Towers Dalal Street,  
Mumbai - 400 001.

**Scrip Code: 544122**

**Head, Listing Compliance Department  
National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051

**Scrip Symbol: ENTERO**

Dear Sir/Madam,

**Subject: Outcome of the Board Meeting**

**Reference: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ("LODR")**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR"), we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. March 21, 2025, inter alia, considered and approved following:

- 1) Acceptance of resignation of Mr. Chebolu Venkataramana Ram from the position of Chief Financial Officer ("CFO") (Key Managerial Personnel) of the Company w.e.f. closure of business hours on April 10, 2025. The Company appreciates the valuable services rendered by him in achieving various milestones during his tenure.

Copy of the resignation letter received from Mr. Chebolu Venkataramana Ram is enclosed as "**Annexure-A**".

- 2) Based on recommendation of Nomination and Remuneration Committee and Audit Committee meeting held on even date, the Board has approved the appointment of Mr. Balakrishnan Natesan Kaushik as Chief Financial Officer ("CFO") designated as Key Managerial Personnel ("KMP") of the Company w.e.f. April 11, 2025.

The details required to be furnished in compliance with Regulation 30 read with Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024, as amended, are enclosed as "**Annexure-B**".

- 3) Approved making of investment upto INR 8 Crores (Indian Rupees Eight Crores Only) in the equity shares proposed to be issued by its wholly owned subsidiary viz. Rada Medisolutions Private Limited, in one or more tranches on rights issue basis.
- 4) Based on recommendation of Audit Committee meeting held on even date, the Board has approved the transfer of the 100% of issued and outstanding equity share capital held by the Company as on the date of transfer, of two of its wholly owned subsidiaries viz., Chethana Pharma Distributors Private Limited ('CPDPL') and CPD Pharma Private Limited ('CPD Pharma'), to its another wholly owned subsidiary, being Rada Medisolutions Private Limited ('Rada').

The details required to be furnished in compliance with Regulation 30 read with Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024, as amended, are enclosed as "**Annexure-C**".

The Board Meeting concluded at 2:15 PM (IST).

This outcome will also be uploaded on the website of the Company.

You are requested to take the same on record.

Yours faithfully,  
**For Entero Healthcare Solutions Limited**

Sanu Kapoor  
**Vice President- General Counsel, Company Secretary  
& Compliance Officer**

Date: 18/2/2025

To

**The Board of Directors**

Entero Healthcare Solutions Limited  
Unit No. 605 & 606, 6th Floor, Trade Centre,  
Bandra Kurla Complex, Mumbai - 400051

Subject: **Resignation** from the position of **Chief Financial Officer** (Key Managerial Personnel)

Dear Sir/Madam,

I am considering a career opportunity outside the organization for better prospects and hereby submitting my resignation to the position of Chief Financial Officer and Key Managerial Personnel of the Company with effect from close hours of **10<sup>th</sup> April' 2025**. Further, I hereby resign and cease to be member of Risk Committee of the company upon approval of my resignation.

There is no other reason for my resignation other than the one mentioned above and I take this opportunity to express my sincere gratitude to Prabhat, Prem and the Board of Directors for their support and guidance during my tenure with the Company.

Additionally, I request the Company to file all the necessary forms with the Registrar of Companies and inform the Stock Exchanges accordingly.

Thank you once again for the opportunity to contribute to the Company's growth.

Yours sincerely,



Chebolu Venkataramana Ram (Cv Ram)

Chief Financial Officer

## Annexure-B

Details w.r.t changes in Key Managerial Personnel in terms of Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024:

Particulars	Details	
Name	Mr. Chebolu Venkataramana Ram	Mr. Balakrishnan Natesan Kaushik
<b>Reason for change viz. appointment, resignation, removal, death or otherwise</b>	Resignation Mr. Chebolu Venkataramana Ram has resigned from the position of the Chief financial Officer (KMP) of the Company, to pursue career opportunity outside the organization for better prospects	Appointment
<b>Date of appointment/cessation (as applicable) and term of appointment</b>	close of business hours on April 10, 2025.	April 11, 2025
<b>Brief Profile (in case of appointment)</b>	Not Applicable	Mr. Balakrishnan Natesan Kaushik holds a Bachelor's degree in Commerce from the University of Mumbai and is a qualified Chartered Accountant.  Mr. Balakrishnan Natesan Kaushik (Mr. Bala) has around 25 years of post-qualification experience in Finance entailing Strategic Planning & Budgeting, Business Restructuring, Costing & Pricing, Working capital Management, Controlling, Financial & Management Accounting, Compliance, Audits & Due Diligence across diverse industries at plant and corporate level. He has multi-cultural/ cross continental exposure having worked with Deloitte, Saint Gobain, Quantum Advisors, Piramal Healthcare, Sandoz, IMS Health and Nestle Skin Health both in India and abroad. He is currently responsible for strategic finance, investor relations, planning, financial reporting, treasury, compliance and controls.

		He has been associated with our Company since June 6, 2018.
<b>Disclosure of relationships between directors (in case of appointment of a director)</b>	Not Applicable	Not Applicable

**Annexure - C**

**Details in terms of Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024:**

Sr. No.	Particulars	Details												
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	<p>The consolidated total income, total revenue from operations and net worth of the Company for the financial year ended 31<sup>st</sup> March 2024 is INR 39,367.23 million, INR 39,223.10 million and INR 16,413.84 million respectively</p> <table border="1" data-bbox="775 725 1468 1124"> <thead> <tr> <th data-bbox="775 725 992 869">Particulars (INR in Millions) (FY24)</th> <th data-bbox="992 725 1203 869">CPDPL</th> <th data-bbox="1203 725 1468 869">CPD Pharma</th> </tr> </thead> <tbody> <tr> <td data-bbox="775 869 992 943"><b>Total income</b></td> <td data-bbox="992 869 1203 943">INR 59.05 [0.15%]</td> <td data-bbox="1203 869 1468 943">INR 82.48 [0.21%]</td> </tr> <tr> <td data-bbox="775 943 992 1048"><b>Total revenue from operations</b></td> <td data-bbox="992 943 1203 1048">INR 57.93 [0.15%]</td> <td data-bbox="1203 943 1468 1048">INR 82.42 [0.21%]</td> </tr> <tr> <td data-bbox="775 1048 992 1124"><b>Net worth</b></td> <td data-bbox="992 1048 1203 1124">INR (16.32) [-0.10%]</td> <td data-bbox="1203 1048 1468 1124">INR (12.56) [-0.08%]</td> </tr> </tbody> </table> <p>CPDPL and CPD Pharma are wholly owned subsidiaries ('WOS') of the Company. The 100% of issued and outstanding equity shares of CPDPL and CPD Pharma are to be transferred to Company's another WOS, being Rada Medisolutions Private Limited ('Rada').</p>	Particulars (INR in Millions) (FY24)	CPDPL	CPD Pharma	<b>Total income</b>	INR 59.05 [0.15%]	INR 82.48 [0.21%]	<b>Total revenue from operations</b>	INR 57.93 [0.15%]	INR 82.42 [0.21%]	<b>Net worth</b>	INR (16.32) [-0.10%]	INR (12.56) [-0.08%]
Particulars (INR in Millions) (FY24)	CPDPL	CPD Pharma												
<b>Total income</b>	INR 59.05 [0.15%]	INR 82.48 [0.21%]												
<b>Total revenue from operations</b>	INR 57.93 [0.15%]	INR 82.42 [0.21%]												
<b>Net worth</b>	INR (16.32) [-0.10%]	INR (12.56) [-0.08%]												
2	Date on which the agreement for sale has been entered into	There is no agreement for sale to be executed.												
3	The expected date of completion of sale/disposal	By 31 <sup>st</sup> May 2025												
4	Consideration received from such sale/disposal	INR 100,000 for transfer of 100% equity stake in CPDPL; and INR 100,000 for transfer of 100% equity stake in CPD Pharma.												
5	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	Rada Medisolutions Private Limited, being the wholly owned subsidiary of the Company, proposes to acquire 100% equity stake of CPDPL and CPD Pharma.												
6	Whether the transaction would fall within related party	Yes												

	transactions? If yes, whether the same is done at “arm’s length”	Given that Rada is wholly owned subsidiary of the Company, even after the proposed transfer, the Company would continue to control 100% equity stake in CPDPL and CPD Pharma
7	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Not applicable – Sale of shares to 100% wholly owned subsidiary
8	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not applicable – Sale of shares